Day One Biopharmaceuticals, Inc.
DAWN
$6.40
$0.101.59%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 5.32% | -68.85% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 5.32% | -68.85% | |||
| Cost of Revenue | -3.29% | 87.55% | |||
| Gross Profit | 6.30% | -71.55% | |||
| SG&A Expenses | -1.38% | 2.63% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -24.02% | 47.43% | |||
| Operating Income | 37.14% | -320.45% | |||
| Income Before Tax | 39.24% | -263.85% | |||
| Income Tax Expenses | -- | 834.01% | |||
| Earnings from Continuing Operations | 45.22% | -277.43% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 45.22% | -277.43% | |||
| EBIT | 37.14% | -320.45% | |||
| EBITDA | 37.80% | -314.00% | |||
| EPS Basic | 45.36% | -267.36% | |||
| Normalized Basic EPS | 39.40% | -254.51% | |||
| EPS Diluted | 45.36% | -268.82% | |||
| Normalized Diluted EPS | 39.40% | -255.04% | |||
| Average Basic Shares Outstanding | 0.26% | 6.02% | |||
| Average Diluted Shares Outstanding | 0.26% | 5.68% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||